How Halozyme, Up 80% This Year, Is Rivaling Merck And Hitting New Highs

Halozyme makes technologies that allow drugs delivered through intravenous infusion, or IV, to instead be given with under-the-skin shots

Investors Business Daily • 2 hours ago

Halozyme to Report Third Quarter 2026 Financial and Operating Results

SAN DIEGO, Oct. 22, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its third quarter 2026 financial and operating results on Thursday, November 5, 2026, following the close of trading. Halozyme will host a conference call on Thursday, November 5, 2026 at 1:30pm PT/4:30pm ET to discuss the results.

PRNewsWire • Oct 22, 2026

Halozyme's Strong Earnings Growth Sends Shares Higher

Halozyme Therapeutics, Inc. (HALO) shares are up 910% since March 2014.

FXEmpire • Oct 21, 2026

5 Strong Buy Growth Stocks With High Margins to Grab Before Earnings

Five Strong Buy stocks stand out ahead of earnings, combining high operating margins, revenue growth and exposure to AI, healthcare, energy and digital payments.

Zacks Investment Research • Oct 21, 2026

Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains

ROST, ROKU, APA, CORT and HALO are five non-tech Nasdaq stocks riding strong growth trends and rising earnings estimates, positioning them for potential gains in Q4.

Zacks Investment Research • Oct 16, 2026

5 Stocks to Buy Using the Relative Price Strength Strategy

HALO, GCT, LIND, PR and CVX stand out as relative strength picks amid market volatility, backed by strong price performance and upbeat earnings estimates.

Zacks Investment Research • Oct 16, 2026

3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)

Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.

Zacks Investment Research • Oct 14, 2026

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Zacks Investment Research • Oct 14, 2026

Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?

Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research • Oct 13, 2026

HALO Wins Court Order Blocking Merck's Keytruda SC in Europe

Halozyme wins a Dutch court order blocking Merck's Keytruda SC in eight European markets, strengthening its position in the patent dispute.

Zacks Investment Research • Oct 8, 2026